menu
    • menu
    [{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"GRC 65327","moa":"Cbl-b","graph1":"Oncology","graph2":"Preclinical","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Glenmark Innovation \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Glenmark Innovation \/ National Cancer Institute"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"ISB 2001","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Glenmark Innovation","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.9299999999999999,"dosageForm":"Injection","sponsorNew":"Ichnos Glenmark Innovation \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Glenmark Innovation \/ AbbVie Inc"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ISB 2001","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Glenmark Innovation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Glenmark Innovation \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"ISB 2001","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Glenmark Innovation \/ Certara","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Glenmark Innovation \/ Certara"}]

    Find Clinical Drug Pipeline Developments & Deals by Ichnos Glenmark Innovation

    Menu

    Ichnos Glenmark Innovation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,925.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AbbVie and IGI Announce Exclusive Global Licensing Agreement for ISB 2001

                            Details : Under the licensing agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan and Greater China.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $700.0 million

                            July 10, 2025

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,925.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IGI gets Fast Track FDA Designation for ISB 2001 in Multiple Myeloma

                            Details : ISB 2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells. It is being investigated for relapsed or refractory multiple myeloma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 05, 2025

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GRC 65327

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IGI and NCI Partner to Test Oral Cbl/b Inhibitor in Triple Negative Breast Cancer

                            Details : Under the agreement, IGI and NCI will collaborate on evaluating IGI's proprietary Cbl/b small molecule, GRC 65327, for treating triple-negative breast cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 30, 2024

                            Lead Product(s) : GRC 65327

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ichnos Glenmark Innovation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Certara

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Certara and Ichnos Glenmark Collaborate On Cancer Drug Dosing Optimization

                            Details : ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Certara

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth